Quel est l’intérêt de la recherche des anticorps anti-nucléolaires dans la sclérodermie systémique ?
| Autor: | Pierre Youinou, M. Padelli, P. Comacle, Yves Renaudineau |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Anoa
Systemic lupus erythematosus Anti-nuclear antibody biology business.industry Biochemistry (medical) Clinical Biochemistry Autoantibody Systemic scleroderma medicine.disease biology.organism_classification Staining Titer Rheumatoid arthritis Immunology medicine skin and connective tissue diseases business |
| Zdroj: | Immuno-analyse & Biologie Spécialisée. 26:176-181 |
| ISSN: | 0923-2532 |
| DOI: | 10.1016/j.immbio.2011.06.003 |
| Popis: | Summary Detected by indirect immunofluorescence, antinucleolar autoantibodies (ANoA) constitute a heterogeneous group of autoantibodies, found in various autoimmune diseases. To assess their importance and clinical interest, we have selected 200 patients with positive ANoA detected between 2007 and 2010. ANoA represent 2.1% of the antinuclear antibodies conducted in the laboratory. ANoA are detected, half in autoimmune diseases (systemic scleroderma [SSc], lupus, rheumatoid arthritis…), and half in other diseases: thrombosis, transplant, cancer… ANoA are rarely indicative of SSc (8,8%) unless they fulfill the following conditions: an elevated titer (> 1/1280), a nucleolar homogeneous staining, and an associated speckled nucleus staining. Such criteria are indicative of anti-PM/Scl or anti-Scl70, two ScS specific autoAb. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect